Specific Features of Allergen-Specific Immunotherapy in Immunocompromised Patients with Pollinosis
Objective of the Paper: To assess the effectiveness of Isoprinosine, an immunomodulatory agent, as a preventive therapy, in combination with allergen-specific immunotherapy (ASIT), in patients with pollinosis (seasonal allergic rhinitis [SAR]) and concomitant secondary immunodeficiency (SID). Study Design: This was an open-label, comparative study. Materials and Methods: We analyzed follow-up and treatment data on 60 patients with pollinosis (SAR) and concomitant SID. These patients were receiving only ASIT (n = 37) or optimized (immunomodulatory) treatment, a combination of ASIT and Isoprinosine (n = 23). Study Results: The study showed that in patients with pollinosis (SAR) and concomitant SID, clinical effects of a combination therapy, including an immunomodulatory agent, were more significant. These effects included the elimination of infection and infection-related symptoms, an improvement in ASIT effects, a normalization of immunologic parameters, and a decrease in total IgE levels. Conclusion: The inclusion of immunomodulator Isoprinosine in a standard combination treatment for patients with pollinosis (SAR) and concomitant SID is safe and clinically effective. This combination normalizes the immune profile, helps treat secondary immunodeficiency, and reduces the frequency of intercurrent infections, thus improving the effectiveness of ASIT.